Mayo Clinic researchers found that cytogenetic subtypes containing three translocations were more common in individuals with a greater proportion of African ancestry.
In granting de novo premarket authorization to ClonoSeq, the agency established its regulatory expectations for similar tests.
These and previously uncovered multiple myeloma risk loci may influence disease by affecting developmental transcriptional regulators.
The platform integrates whole exome and RNA sequencing for downstream RNA-based drug repurposing to treat patients with relapsed multiple myeloma.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.
The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.
The researchers found that both coding and non-coding alterations drive the early development of multiple myeloma.
The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.
Researchers found rare mutations in USP45 and ARID1A by applying a shared genomic segment mapping approach to several large multiple myeloma-affected families.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.